Loading clinical trials...
Loading clinical trials...
A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
CBP-201
Placebo
Locations
48
China
Connect Investigative Site 33
Hefei, Anhui, China
Connect Investigative Site 01
Beijing, Beijing Municipality, China
Connect Investigative Site 02
Beijing, Beijing Municipality, China
Connect Investigative Site 03
Beijing, Beijing Municipality, China
Connect Investigative Site 17
Beijing, Beijing Municipality, China
Connect Investigative Site 47
Beijing, Beijing Municipality, China
Start Date
August 31, 2021
Primary Completion Date
December 1, 2022
Completion Date
September 28, 2023
Last Updated
May 1, 2024
NCT07321951
NCT03057860
NCT06158490
NCT07344051
NCT05590585
NCT05899816
Lead Sponsor
Connect Biopharm LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions